Deng X, Liu Y, Zhan X, Chen T, Jiang M, Jiang X, et al. Trends in incidence, mortality, and survival of penile cancer in the United States: a population-based study. Front Oncol. 2022; https://doi.org/10.3389/fonc.2022.891623.

Article  PubMed  PubMed Central  Google Scholar 

Longoni M, Fankhauser CD, Negri F, Salonia A, Basile G, Johnstone PAS, et al. Treatment strategies in human papillomavirus-related advanced penile cancer. Nat Rev Urol. 2025; https://doi.org/10.1038/s41585-025-00994-z.

Article  PubMed  Google Scholar 

Udager AM, Liu T‑Y, Skala SL, Magers MJ, McDaniel AS, Spratt DE, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016;27:1706–12. https://doi.org/10.1093/annonc/mdw216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brouwer OR, Albersen M, Parnham A, Protzel C, Pettaway CA, Ayres B, et al. European association of urology-American society of clinical oncology collaborative guideline on penile cancer: 2023 update. Eur Urol. 2023;83:548–60. https://doi.org/10.1016/j.eururo.2023.02.027.

Article  PubMed  Google Scholar 

https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. Accessed 15 May 2025.

Muneer A, Bandini M, Compérat E, De Meerleer G, Fizazi K, Gietema J, et al. Penile cancer: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2024;9:103481. https://doi.org/10.1016/j.esmoop.2024.103481.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, et al. Cisplatin and 5‑fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012; https://doi.org/10.1111/j.1464-410X.2012.11453.x.

Article  PubMed  Google Scholar 

Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, Ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. JCO. 2010;28:3851–7. https://doi.org/10.1200/JCO.2010.29.5477.

Article  CAS  Google Scholar 

Shammas FV, Ous S, Fossa SD. Cisplatin and 5‑Fluorouracil in advanced cancer of the penis. J Urol. 1992;147:630–2. https://doi.org/10.1016/S0022-5347(17)37327-5.

Article  CAS  PubMed  Google Scholar 

Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109:2554–9. https://doi.org/10.1038/bjc.2013.620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Zhu Y, Ye D. Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget. 2015;6:32212–9. https://doi.org/10.18632/oncotarget.4802.

Article  PubMed  PubMed Central  Google Scholar 

Nicholson S, Tovey H, Elliott T, Burnett SM, Cruickshank C, Bahl A, et al. VincaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. Br J Cancer. 2022;126:34–41. https://doi.org/10.1038/s41416-021-01574-9.

Article  CAS  PubMed  Google Scholar 

Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753–8. https://doi.org/10.1158/1078-0432.CCR-18-4070.

Article  CAS  PubMed  Google Scholar 

de Vries HM, Rafael TS, Gil-Jimenez A, de Feijter JM, Bekers E, van der Laan E, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the PERICLES study): a phase II trial. JCO. 2023;41:4872–80. https://doi.org/10.1200/JCO.22.02894.

Article  CAS  Google Scholar 

García Del Muro X, Páez López-Bravo D, Cuéllar-Rivas MA, Maroto P, Giannatempo P, Castellano D, et al. Retifanlimab in advanced penile squamous cell carcinoma: the phase 2 ORPHEUS study. Eur Urol Oncol. 2025;8:278–86. https://doi.org/10.1016/j.euo.2024.04.021.

Article  PubMed  Google Scholar 

McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021;127:840–9. https://doi.org/10.1002/cncr.33328.

Article  CAS  PubMed  Google Scholar 

Necchi A, Spiess PE, Bandini M, Basile G, Grivas P, Bratslavsky G, et al. Advanced squamous cell carcinomas of the pelvic and perineal region: a comprehensive genomic profiling study. Oncologist. 2022;27:1016–24. https://doi.org/10.1093/oncolo/oyac144.

Article  PubMed  PubMed Central  Google Scholar 

Necchi A, Vullo LS, Perrone F, Raggi D, Giannatempo P, Calareso G, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 2018;121:348–56. https://doi.org/10.1111/bju.14013.

Article  CAS  PubMed  Google Scholar 

Fahey CC, Nebhan CA, York S, Davis NB, Hurley PJ, Gordetsky JB, et al. Metastatic penile squamous cell carcinoma responsive to enfortumab vedotin. Int J Mol Sci. 2023; https://doi.org/10.3390/ijms242216109.

Article  PubMed  PubMed Central  Google Scholar 

Maluf FC, Trindade K, Preto DDA, Monteiro FSM, Luz M, Beato PM, et al. A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. JCO. 2024;42:5009–5009. https://doi.org/10.1200/JCO.2024.42.16_suppl.5009.

Article  Google Scholar 

Bahl A, et al. EPIC-A: phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. JCO. 2025;43.

Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113:871–7. https://doi.org/10.1111/bju.12450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, et al. Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with Ipilimumab for advanced/metastatic genitourinary tumors. JCO. 2024;42:3033–46. https://doi.org/10.1200/JCO.23.02233.

Article  CAS  Google Scholar 

Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011;60:1280–4. https://doi.org/10.1016/j.eururo.2011.08.028.

Article  CAS  PubMed  Google Scholar 

Challapalli A, Pearson S, Mitra AV, Coe M, Thomson A, Elliott T, et al. A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis. J Int Med Res. 2019;47:4664–72. https://doi.org/10.1177/0300060519863546.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113:871–7. https://doi.org/10.1111/bju.12450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Necchi A, Giannatempo P, Vullo LS, Raggi D, Nicolai N, Colecchia M, et al. Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed. Clin Genitourin Cancer. 2016;14:231–6. https://doi.org/10.1016/j.clgc.2015.08.001.

Article  PubMed  Google Scholar 

Challapalli A, et al. EPIC-B: phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. JCO. 2025;43.

El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the global society of rare genitourinary tumors. J Natl Cancer Inst. 2023;115:1605–15. https://doi.org/10.1093/jnci/djad155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Q, Li Y, Zhang Y, Deng Z, Ding Y. Case report of penile squamous cell carcinoma continuous treatment with BRCA 2 mutation. World J Surg Oncol. 2024;22:50. https://doi.org/10.1186/s12957-024-03305-9.